in primary human T cells, and addition of anti-CD28 antibodies relieved this suppression. Using enhancer-reporter constructs, EL-4 specifically down-regulated the NFEL-2B element. Electrophoretic mobility shift assays using a DNA oligomer containing the NFIL-2B binding site indicated that IL-4 inhibited the NFIL-2B complex and that the NFIL-2B DNA binding factor is distinct from AP-1. These results suggest that may regulate development and function of T-cell subsets involved in cell-mediated immunity in part by inhibiting factors required for transcription of the IL2 gene.
Functional T-cell subsets have been defined in human and mouse cells by their surface markers and the patterns of lymphokines produced. Type 1 CD4 (Thl) and CD8 (cytotoxic T lymphocyte) T cells producing interleukin 2 (IL-2) and interferon y (IFN-y) serve as effector cells for cellmediated immunity, whereas type 2 CD4 (Th2) cells that regulate antibody formation and type 2 CD8 T cells that have suppressor activity produce interleukin 4 (IL-4) (1-3). has been shown to exert immunosuppressive effects on cell-mediated immunity and resistance to Leishmania and Schistosome parasites in murine systems (4, 5) . CD8 T cells with mRNA for predominate in lesions of antigenunresponsive patients with lepromatous leprosy (6) . Clones of such T cells suppress in vitro responses of antigenresponsive CD4 cells, and production of IL-4 appears to be a necessary condition for in vitro suppression by many (3) if not all (39) . The present work explores the hypothesis that the suppressive effects of IL-4 result from transcriptional downregulation of lymphokine genes functionally required by type 1 T cells to generate cell-mediated responses, particularly IL2 and IFNG (IFN-y gene).
MATERIALS AND METHODS
Cell Culture, Lymphokines, and Antibodies. lacZ Jurkat lines were kindly provided by L. A. Herzenberg (Stanford, CA) and grown as described (7) . Recombinant human IL-4 (specific activity, 107 units/mg) was generously provided by P. Trotta (Schering, Bloomfield, NJ). Phorbol 12-myristate 13-acetate (PMA) was obtained from Sigma. Ionomycin was obtained from Calbiochem. The monoclonal antibody (mAb)
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Exponentially growing Jurkat, Raji, and U937 cells were seeded at 3 x 105 per ml with or without IL-4 (500 units/ml). Cells were incubated for 24 f-Galactosidase and luciferase assays were done as described (7, 9 Electrophoretic mobility shift assays were performed as described (7) . Nonlabeled oligo was added 10 min before addition of the probe in competition experiments. c-Jun protein (4 foot-printing units, Promega) was added to the nuclear extracts 10 min before addition of the probe in competition experiments.
RESULTS
Suppression of IL2 Expression by IL-4. Jurkat cells have long served as a useful human T-cell model for study of transcriptional regulation of the IL2 gene. Stimulation with ionomycin and PMA mimics the effect of T-cell receptorinduced activation of phospholipase C and protein kinase C, respectively, thereby inducing IL2 gene transcription. When we pretreated Jurkat cells with IL-4, an 80% decrease in IL2 mRNA production was observed (Fig. 1) . This suppression could be attributed entirely to a decrease in the rate of lL2 gene transcription, since the half-life of the mRNA was unaffected ( Fig. 2A) . Of interest, addition of an antibody to CD28, a costimulatory signal, relieved this suppression (Fig.  1) . To ascertain the biological significance of these findings with the Jurkat cell line, we measured the effect of IL-4 on steady-state mRNA levels in primary PBLs. Northern analysis indicated that the transcriptional down-regulation of the IV gene by IL-4 observed in Jurkat cells faithfully reflected that in primary T cells (Fig. 2B ). In addition, these experiments showed that the IFNG gene was also down-regulated by IL-4. A recent study in mouse (11) and the present study in human cells (Fig. 2C ) demonstrate that a minimum of 12 hr of IL-4 pretreatment is required for suppression of lL2 mRNA levels to be manifest.
IL-4 Selectively Inhibits NFIL-2B. Transcription of the IL2 gene is regulated primarily through the 5' flanking region 326 bp upstream ofthe transcription start site (12) . Since many of the binding sites for nuclear factors in this region are known (13-16), we sought to assay these enhancer elements independently to determine if any was inhibited by IL-4 pretreatment. One 5' element of the IL2 gene, termed NFIL-2B, originally defined as being protected from DNase I attack upon T-cell activation and essential to transcriptional activation of the IL2 gene by deletion analysis (14) , was of particular interest because it has been identified as the element sensitive to cyclosporin A (7), glucocorticoids (17, 18) , and clonal anergy (19) . Using Jurkat cells transformed initially with a series of integrated ,B-galactosidase reporter constructs, we found the NFIL-2B enhancer element was reduced 50%o in transcriptional activity by IL-4 pretreatment, whereas the NF-AT and Oct-i enhancer elements were not affected (Fig. 3A) . The NFkB enhancer element was slightly inhibited by IL-4. Since the IL-4 effects on the enhancer elements did not reflect the expected results based on the experiments with the endogenous II2 gene, we reasoned that this was due to position effects ofthe integrated reporters. To establish that the IL-4 effects on the NFIL-2B element and the entire IL2 enhancer were substantial, transient transfection assays were carried out with luciferase reporter plasmids (Fig. 3) . These experiments clearly confirmed that IL-4 pretreatment prevents transcription of the IL2 gene by inhibiting the NFIL-2B element. The inhibition of NFIL-2B enhancer activity resulting from IL-4 pretreatment can be explained by our observation that the NFIL-2B complex is not formed in gel shift assays with nuclear extracts from cells treated with IL-4 prior to stimulation (Fig. 4A) . In controls we observed that IL-4 pretreatment had no effect on the AP-1 and NF-AT complexes as assayed by gel shifts (Figs. 4 B and  C) .
NFIL-2B Is a Transcription Factor Distinct from AP-1. The NFIL-2B element contains a putative AP-1 binding site, TRE (AGAGTCA), and it has been demonstrated that partially purified AP-1 will bind to this site (20) . It is also known that the IL2 gene is regulated by Fos and Jun proteins (21) . Based on these data several groups inferred that the NFIL-2B element is merely an AP-1 site. To clarify the issue, we analyzed the factors that bind this element in greater detail. In electrophoretic mobility shift assays using the -159 to -134 region as a probe with nuclear extracts from unstimulated Jurkat cells, two complexes were observed (Fig. 5A , lane 2). When gel shifts were performed with an oligo mutated in the two major AP-1 contact bases (NFIL-2Bm), which reduces its capacity to bind AP-1 >100-fold (22) , only the lower complex was formed (Fig. SA, lane 3) . Since it is known that c-Jun is constitutively produced, but that c-Fos is induced upon stimulation (23) (Fig. SA, lanes  7-13) . If the only function of the NFIL-2B element were to bind AP-1, then the unlabeled AP-1 metallothionine oligo would be expected to competitively inhibit the NFIL-2B gel shift. Fig. 5A (lanes 8, 11, and 13) demonstrates that the unlabeled AP-1 oligo failed to competitively inhibit the NFIL-2B gel shift in nuclear extracts from stimulated cells. These two sets of experiments together provide compelling evidence that the DNA binding in the NFIL-2B complex is not mediated by AP-1.
It was surprising that the NFIL-2B gel shift was generated when the unlabeled AP-1 oligo was added to extracts from unstimulated cells (Fig. 5A, lanes 7, 10, and 12 ). This result suggested that in unstimulated cells, the NFIL-2B factor may be bound to an inhibitor that prevents it from binding DNA. The (Fig. 4A, lanes 1 and 4) , unless the unlabeled AP-1 oligo was added (Fig. 5A, lanes 7 and 9) . These results demonstrate that IL-4 pretreatment does not prevent the expression of the NFIL-2B factor but blocks some modification that enables it to bind DNA following stimulation. As predicted by the inhibitor model, the ability of the unlabeled AP-1 oligo to generate the NFIL-2B gel shift in nuclear extracts from unstimulated cells was concentration dependent (Fig. SB) . Less than 20 ng of unlabeled oligo was insufficient to liberate NFIL-2B and >20 ug of oligo nonspecifically inhibited the NFIL-2B gel shift. We then tested the possibility that the inhibitor might be c-Jun. The NFIL-2B DNA complex generated with unstimulated nuclear extracts (Fig. SC, lane 2) was dissociated and competitively inhibited by the addition of purified c-Jun homodimers (lane 3), but not 20 ug of bovine serum albumin, an irrelevant protein (data not shown).
DISCUSSION
The data of the present study clearly indicate the existence of a DNA binding factor distinct from AP-1 that binds to the sequence defined by Durand et al. (14) as NFIL-2B and that is present in resting and stimulated T-cell, B-cell, and macrophage cell lines (Fig. SA) model in which NFIL-2B in resting cells is bound to an inhibitor, most probably Jun homodimers, and is not free to bind the enhancer until c-Fos is induced by stimulation and the AP-1 heterodimer forms, or a post-translational modification releases the factor. There are multiple additional lines of evidence consistent with our interpretation that the NFIL-2B factor is distinct from AP-1 and essential for IL2 gene regulation: (i) the -159 to -151 deletion mutant, which leaves a putative AP-1 binding site intact, exhibits an 89% loss of transcription (14); (ii) the core AP-1-like sequence of the NFIL-2B site, AGAGTCA, does not bind Jun/Fos heterodimers (24); (iii) the transversion of the T in the first position of the putative AP-1 site in the NFIL-2B element results in the total loss ofAP-1 transactivation by this element (25) ; (iv) from crystallographic data the conserved methyl group from an alanine residue found in all TRE binding bZIP proteins, including Fos and Jun, can bind only to a T in the consensus sequence, and not an A as found in NFIL-2B (26) ; (v) activation ofthe NFIL-2B site in vivo requires stimulation by PMA and ionomycin, whereas a construct containing a consensus AP-1 site is inducible with PMA alone (7); (vi) the NFIL-2B enhancer is sensitive to cyclosporin A and FK506, whereas the AP-1 is not (7); (vii) largely overlooked evidence indicates that the NFIL-2B enhancer, and not AP-1 binding, is depressed in anergic T cells (27) ; and (viii) as we have demonstrated here, the NFIL-2B gel shift is sensitive to IL-4 pretreatment, whereas the AP-1 gel shift is not. These data argue that the factor that is important for transcription of the , generated by adding stimulated nuclear extracts to radiolabeled NFIL-2B oligo in the presence of unlabeled AP-1 oligo, was not formed when c-Jun protein was added to the nuclear extract prior to addition of the probe (lanes 3 and 4) . Lane IL2 gene and binds to the NFIL-2B enhancer element is distinct from AP-1.
It has also been found that the NF-AT and NFIL-2B elements act synergistically (17) and both elements have been reported to interact with AP-1-like factors (28) (29) (30) . However, since the DNA binding proteins that recognized these elements are distinct from AP-1, a model is suggested in which the NF-AT and NFIL-2B elements, both essential for IL2 transcription, may interact by binding the c-Jun and c-Fos components of AP-1, perhaps after its phosphorylation (31) following T-cell activation, to form a transcriptional complex, similar to the original proposal for AP-1 transcriptional activation (32) . The interaction of all three factors could best be accomplished by a loop, suggested in other systems to explain how enhancing elements situated at a distance from the transcriptional start site act to regulate transcription (33, 34) . The CD28 signal may relieve the IL-4-induced suppression, possibly by stabilizing IL2 transcripts (35) or by compensating for the absence of the NFIL-2B complex by the CD28-induced nuclear factor, CD28RC, which binds to the site precisely adjacent to the NFIL-2B binding site (16) .
Mechanisms of peripheral tolerance-T-cell suppression and clonal anergy-appear to share many similarities. Our findings suggest that the transcriptional regulation of the 1L2 gene by IL-4 is very similar to that recently described in anergic T cells (19) . As in anergy, IL-4 pretreatment did not block the induction of c-fos mRNA (data not shown). Although the precise molecular mechanism by which the NFIL-2B enhancer is negatively regulated in all of these systems remains to be elucidated, our data indicate that does not affect the expression of the NFIL-2B factor (Fig.  5A, lane 9) . Thus possible mechanisms of suppression could be through post-translational modifications, as described for other transcription factors (36) , or induction of a novel factor yet to be identified.
Overall, these results indicate that one mechanism by which IL-4 down-regulates IL-2 production is by inhibition of the transcription factor complex, NFIL-2B. The complete role of IL-4 in regulation of T-cell subsets remains to be elucidated. It is clear that IL-4 inhibits the expression of protective cell-mediated immunity in several infectious disease models. Not only may IL-4 serve as a growth factor for type 2 CD4 (Th2) cells (37, 38) , and suppress functions oftype 1 CD4 (Thi) cells, but it also may act to suppress the differentiation of virgin T cells to type 1 T cells by inhibiting production of IL-2 required for their expansion.
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